Search

Your search keyword '"Siebenhuener, Alexander"' showing total 27 results
Start Over Author "Siebenhuener, Alexander"
27 results on '"Siebenhuener, Alexander"'

1. Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer: A Multicenter Phase Ib Trial (RECAP)–SAKK 41/16

Author

Bastian, Sara, Joerger, Markus, Holer, Lisa, Bärtschi, Daniela, Guckenberger, Matthias, Jochum, Wolfram, Koeberle, Dieter, Siebenhüner, Alexander R., Wicki, Andreas, Berger, Martin D., Winterhalder, Ralph C., Largiadèr, Carlo R., Löffler, Melanie, Mosna-Firlejczyk, Katarzyna, Maranta, Angela Fischer, Pestalozzi, Bernhard C., Csajka, Chantal, and von Moos, Roger

Published
2024
Full Text
View/download PDF

2. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

Author

Nesti, Cédric, Bräutigam, Konstantin, Benavent, Marta, Bernal, Laura, Boharoon, Hessa, Botling, Johan, Bouroumeau, Antonin, Brcic, Iva, Brunner, Maximilian, Cadiot, Guillaume, Camara, Maria, Christ, Emanuel, Clerici, Thomas, Clift, Ashley K, Clouston, Hamish, Cobianchi, Lorenzo, Ćwikła, Jarosław B, Daskalakis, Kosmas, Frilling, Andrea, Garcia-Carbonero, Rocio, Grozinsky-Glasberg, Simona, Hernando, Jorge, Hervieu, Valérie, Hofland, Johannes, Holmager, Pernille, Inzani, Frediano, Jann, Henning, Jimenez-Fonseca, Paula, Kaçmaz, Enes, Kaemmerer, Daniel, Kaltsas, Gregory, Klimacek, Branislav, Knigge, Ulrich, Kolasińska-Ćwikła, Agnieszka, Kolb, Walter, Kos-Kudła, Beata, Kunze, Catarina Alisa, Landolfi, Stefania, La Rosa, Stefano, López, Carlos López, Lorenz, Kerstin, Matter, Maurice, Mazal, Peter, Mestre-Alagarda, Claudia, del Burgo, Patricia Morales, van Dijkum, Els J M Nieveen, Oleinikov, Kira, Orci, Lorenzo A, Panzuto, Francesco, Pavel, Marianne, Perrier, Marine, Reims, Henrik Mikael, Rindi, Guido, Rinke, Anja, Rinzivillo, Maria, Sagaert, Xavier, Satiroglu, Ilker, Selberherr, Andreas, Siebenhüner, Alexander R, Tesselaar, Margot E T, Thalhammer, Michael J, Thiis-Evensen, Espen, Toumpanakis, Christos, Vandamme, Timon, van den Berg, José G, Vanoli, Alessandro, van Velthuysen, Marie-Louise F, Verslype, Chris, Vorburger, Stephan A, Lugli, Alessandro, Ramage, John, Zwahlen, Marcel, Perren, Aurel, and Kaderli, Reto M

Published
2023
Full Text
View/download PDF

3. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

Author

Scheiner, Bernhard, Roessler, Daniel, Phen, Samuel, Lim, Mir, Pomej, Katharina, Pressiani, Tiziana, Cammarota, Antonella, Fründt, Thorben W., von Felden, Johann, Schulze, Kornelius, Himmelsbach, Vera, Finkelmeier, Fabian, Deibel, Ansgar, Siebenhüner, Alexander R., Shmanko, Kateryna, Radu, Pompilia, Schwacha-Eipper, Birgit, Ebert, Matthias P., Teufel, Andreas, Djanani, Angela, Hucke, Florian, Balcar, Lorenz, Philipp, Alexander B., Hsiehchen, David, Venerito, Marino, Sinner, Friedrich, Trauner, Michael, D'Alessio, Antonio, Fulgenzi, Claudia A.M., Pinato, David J., Peck-Radosavljevic, Markus, Dufour, Jean-François, Weinmann, Arndt, Kremer, Andreas E., Singal, Amit G., De Toni, Enrico N., Rimassa, Lorenza, and Pinter, Matthias

Published
2023
Full Text
View/download PDF

4. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy

Author

Hirt, Christian K., Booij, Tijmen H., Grob, Linda, Simmler, Patrik, Toussaint, Nora C., Keller, David, Taube, Doreen, Ludwig, Vanessa, Goryachkin, Alexander, Pauli, Chantal, Lenggenhager, Daniela, Stekhoven, Daniel J., Stirnimann, Christian U., Endhardt, Katharina, Ringnalda, Femke, Villiger, Lukas, Siebenhüner, Alexander, Karkampouna, Sofia, De Menna, Marta, Beshay, Janette, Klett, Hagen, Kruithof-de Julio, Marianna, Schüler, Julia, and Schwank, Gerald

Published
2022
Full Text
View/download PDF

5. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Author

Muñoz-Martínez, Sergio, Sapena, Victor, Forner, Alejandro, Nault, Jean-Charles, Sapisochin, Gonzalo, Rimassa, Lorenza, Sangro, Bruno, Bruix, Jordi, Sanduzzi-Zamparelli, Marco, Hołówko, Wacław, El Kassas, Mohamed, Mocan, Tudor, Bouattour, Mohamed, Merle, Philippe, Hoogwater, Frederik J.H., Alqahtani, Saleh A., Reeves, Helen L., Pinato, David J., Giorgakis, Emmanouil, Meyer, Tim, Villadsen, Gerda Elisabeth, Wege, Henning, Salati, Massimiliano, Mínguez, Beatriz, Di Costanzo, Giovan Giuseppe, Roderburg, Christoph, Tacke, Frank, Varela, María, Galle, Peter R., Alvares-da-Silva, Mario Reis, Trojan, Jörg, Bridgewater, John, Cabibbo, Giuseppe, Toso, Christian, Lachenmayer, Anja, Casadei-Gardini, Andrea, Toyoda, Hidenori, Lüdde, Tom, Villani, Rosanna, Matilla Peña, Ana María, Guedes Leal, Cassia Regina, Ronzoni, Monica, Delgado, Manuel, Perelló, Christie, Pascual, Sonia, Lledó, José Luis, Argemi, Josepmaria, Basu, Bristi, da Fonseca, Leonardo, Acevedo, Juan, Siebenhüner, Alexander R., Braconi, Chiara, Meyers, Brandon M., Granito, Alessandro, Sala, Margarita, Rodríguez-Lope, Carlos, Blaise, Lorraine, Romero-Gómez, Manuel, Piñero, Federico, Gomez, Dhanny, Mello, Vivianne, Pinheiro Alves, Rogerio Camargo, França, Alex, Branco, Fernanda, Brandi, Giovanni, Pereira, Gustavo, Coll, Susanna, Guarino, Maria, Benítez, Carlos, Anders, Maria Margarita, Bandi, Juan C., Vergara, Mercedes, Calvo, Mariona, Peck-Radosavljevic, Markus, García-Juárez, Ignacio, Cardinale, Vincenzo, Lozano, Mar, Gambato, Martina, Okolicsanyi, Stefano, Morales-Arraez, Dalia, Elvevi, Alessandra, Muñoz, Alberto E., Lué, Alberto, Iavarone, Massimo, and Reig, Maria

Published
2021
Full Text
View/download PDF

6. Community-driven development of a modified progression-free survival ratio for precision oncology

Author

Mock, Andreas, Heilig, Christoph E, Kreutzfeldt, Simon, Huebschmann, Daniel, Heining, Christoph, Schröck, Evelin, Brors, Benedikt, Stenzinger, Albrecht, Jäger, Dirk, Schlenk, Richard, Glimm, Hanno, Fröhling, Stefan, Horak, Peter, Apostolidis, Leonidas, Augustin, Marinela, Aust, Daniela, Bhatti, Irfan Ahmed, Bloehdorn, Johannes, Brendel, Cornelia, Britschgi, Christian, Braess, Jan, Burdach, Stefan, Busch, Elena, Casuscelli, Jozefina, Desuki, Alexander, Deutsch, Thomas, Dietrich, Mareike, Ehmer, Ursula, Ettrich, Thomas J, Falkenhorst, Johanna, Fehm, Tanja, Flörcken, Anne, Forschner, Andrea, Fuxius, Stefan, Gonzales-Carmona, Maria, Griesinger, Frank, Grill, Sabine, Gröschel, Stefan, Haag, Georg Martin, Haag, Ulrich, Halama, Niels, Hebart, Holger, Heidger, Nina, Hermes, Barbara, Hess, Georg, Hettmer, Simone, Hoechstetter, Manuela, Hoffmann, Martin, Hüttner, Felix J, Illert, Anna L, Jenzer, Maximilian, Kasper, Bernd, Kasper-Virchow, Stefan, Kindler, Thomas, Koscielniak, Ewa, Krönke, Jan, Kühn, Michael, Kunzmann, Volker, Lang, Alois, Leichsenring, Jonas, Livingstone, Elisabeth, Liotta, Lucia, Luley, Kim, Mack, Elisabeth, Martens, Uwe M, Metzeler, Klaus, Middeke, Jan Moritz, Möhrmann, Lino, Jayarama-Naidu, Roopa, Pape, Ulrich-Frank, Perkhofer, Lukas, Pfeufer, Arne, Pixberg, Constantin, Quante, Michael, Rendenbach, Bernhard, Rieke, Damian, Rothermundt, Christian, Sagerer, Andre Norbert, Salzmann, Martin, Saur, Dieter, Schilling, Bastian, Schleicher, Jan, Schlenska-Lange, Anke, Schmidt, Thomas, Schmitz, Sophia, Schölch, Sebastian, Shah, Rajiv, Shoumariyeh, Khalid, Siebenhüner, Alexander, Singh, Martin, Siveke, Jens, Springfeld, Christoph, Starke, Helen, Strobel, Sophia, Teleanu, Veronica, Thon, Niklas, Wagner, Sebastian, Walle, Thomas, Westphalen, Benedikt, Whitlock, Bettina, Winkler, Eva, Wirsik, Naita Maren, Woydack, Lena, Bois, Angelika Zabel-du, and Zschäbitz, Stefanie

Published
2019
Full Text
View/download PDF

8. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.

Author

Lorenzen, Sylvie, Götze, Thorsten Oliver, Thuss-Patience, Peter, Biebl, Matthias, Homann, Nils, Schenk, Michael, Lindig, Udo, Heuer, Vera, Kretzschmar, Albrecht, Goekkurt, Eray, Haag, Georg Martin, Riera-Knorrenschild, Jorge, Bolling, Claus, Hofheinz, Ralf-Dieter, Zhan, Tianzuo, Angermeier, Stefan, Ettrich, Thomas Jens, Siebenhuener, Alexander Reinhard, Elshafei, Moustafa, and Bechstein, Wolf Otto

Published
2024
Full Text
View/download PDF

9. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST

Author

de Mestier, Louis, primary, Resche‐Rigon, Matthieu, additional, Dromain, Clarisse, additional, Lamarca, Angela, additional, La Salvia, Anna, additional, de Baker, Lesley, additional, Fehrenbach, Uli, additional, Pusceddu, Sara, additional, Colao, Annamaria, additional, Borbath, Ivan, additional, de Haas, Robbert, additional, Rinzivillo, Maria, additional, Zerbi, Alessandro, additional, Funicelli, Luigi, additional, de Herder, Wouter W., additional, Selberherr, Andreas, additional, Wagner, Anna Dorothea, additional, Manoharan, Prakash, additional, De Cima, Andrea, additional, Lybaert, Willem, additional, Jann, Henning, additional, Prinzi, Natalie, additional, Faggiano, Antongiulio, additional, Annet, Laurence, additional, Walenkamp, Annemiek, additional, Panzuto, Francesco, additional, Pedicini, Vittorio, additional, Pitoni, Maria Giovanna, additional, Siebenhuener, Alexander, additional, Mayerhoefer, Marius E., additional, Ruszniewski, Philippe, additional, and Vullierme, Marie‐Pierre, additional

Published
2023
Full Text
View/download PDF

10. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors:Alternatives to RECIST

Author

de Mestier, Louis, Resche-Rigon, Matthieu, Dromain, Clarisse, Lamarca, Angela, La Salvia, Anna, de Baker, Lesley, Fehrenbach, Uli, Pusceddu, Sara, Colao, Annamaria, Borbath, Ivan, de Haas, Robbert, Rinzivillo, Maria, Zerbi, Alessandro, Funicelli, Luigi, de Herder, Wouter W., Selberherr, Andreas, Wagner, Anna Dorothea, Manoharan, Prakash, De Cima, Andrea, Lybaert, Willem, Jann, Henning, Prinzi, Natalie, Faggiano, Antongiulio, Annet, Laurence, Walenkamp, Annemiek, Panzuto, Francesco, Pedicini, Vittorio, Pitoni, Maria Giovanna, Siebenhuener, Alexander, Mayerhoefer, Marius E., Ruszniewski, Philippe, Vullierme, Marie Pierre, de Mestier, Louis, Resche-Rigon, Matthieu, Dromain, Clarisse, Lamarca, Angela, La Salvia, Anna, de Baker, Lesley, Fehrenbach, Uli, Pusceddu, Sara, Colao, Annamaria, Borbath, Ivan, de Haas, Robbert, Rinzivillo, Maria, Zerbi, Alessandro, Funicelli, Luigi, de Herder, Wouter W., Selberherr, Andreas, Wagner, Anna Dorothea, Manoharan, Prakash, De Cima, Andrea, Lybaert, Willem, Jann, Henning, Prinzi, Natalie, Faggiano, Antongiulio, Annet, Laurence, Walenkamp, Annemiek, Panzuto, Francesco, Pedicini, Vittorio, Pitoni, Maria Giovanna, Siebenhuener, Alexander, Mayerhoefer, Marius E., Ruszniewski, Philippe, and Vullierme, Marie Pierre

Abstract

RECIST 1.1 criteria are commonly used with computed tomography (CT) to evaluate the efficacy of systemic treatments in patients with neuroendocrine tumors (NETs) and liver metastases (LMs), but their relevance is questioned in this setting. We aimed to explore alternative criteria using different numbers of measured LMs and thresholds of size and density variation. We retrospectively studied patients with advanced pancreatic or small intestine NETs with LMs, treated with systemic treatment in the first-and/or second-line, without early progression, in 14 European expert centers. We compared time to treatment failure (TTF) between responders and non-responders according to various criteria defined by 0%, 10%, 20% or 30% decrease in the sum of LM size, and/or by 10%, 15% or 20% decrease in LM density, measured on two, three or five LMs, on baseline (≤1 month before treatment initiation) and first revaluation (≤6 months) contrast-enhanced CT scans. Multivariable Cox proportional hazard models were performed to adjust the association between response criteria and TTF on prognostic factors. We included 129 systemic treatments (long-acting somatostatin analogs 41.9%, chemotherapy 26.4%, targeted therapies 31.8%), administered as first-line (53.5%) or second-line therapies (46.5%) in 91 patients. A decrease ≥10% in the size of three LMs was the response criterion that best predicted prolonged TTF, with significance at multivariable analysis (HR 1.90; 95% CI: 1.06–3.40; p =.03). Conversely, response defined by RECIST 1.1 did not predict prolonged TTF (p =.91), and neither did criteria based on changes in LM density. A ≥10% decrease in size of three LMs could be a more clinically relevant criterion than the current 30% threshold utilized by RECIST 1.1 for the evaluation of treatment efficacy in patients with advanced NETs. Its implementation in clinical trials is mandatory for prospective validation. Criteria based on changes in LM density were not predictive of treatment

Published
2023

12. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score

Author

Scheiner, Bernhard, Pomej, Katharina, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Waidmann, Oliver, Himmelsbach, Vera, Schulze, Kornelius, von Felden, Johann, Frundt, Thorben W., Stadler, Marc, Heinzl, Harald, Shmanko, Kateryna, Spahn, Stephan, Radu, Pompilia, Siebenhuener, Alexander R., Mertens, Joachim C., Rahbari, Nuh N., Kuetting, Fabian, Waldschmidt, Dirk-Thomas, Ebert, Matthias P., Teufel, Andreas, De Dosso, Sara, Pinato, David J., Pressiani, Tiziana, Meischl, Tobias, Balcar, Lorenz, Mueller, Christian, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Personeni, Nicola, Rimassa, Lorenza, Bitzer, Michael, Trojan, Joerg, Weinmann, Arndt, Wege, Henning, Dufour, Jean-Francois, Peck-Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias, Scheiner, Bernhard, Pomej, Katharina, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Waidmann, Oliver, Himmelsbach, Vera, Schulze, Kornelius, von Felden, Johann, Frundt, Thorben W., Stadler, Marc, Heinzl, Harald, Shmanko, Kateryna, Spahn, Stephan, Radu, Pompilia, Siebenhuener, Alexander R., Mertens, Joachim C., Rahbari, Nuh N., Kuetting, Fabian, Waldschmidt, Dirk-Thomas, Ebert, Matthias P., Teufel, Andreas, De Dosso, Sara, Pinato, David J., Pressiani, Tiziana, Meischl, Tobias, Balcar, Lorenz, Mueller, Christian, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Personeni, Nicola, Rimassa, Lorenza, Bitzer, Michael, Trojan, Joerg, Weinmann, Arndt, Wege, Henning, Dufour, Jean-Francois, Peck-Radosavljevic, Markus, Vogel, Arndt, and Pinter, Matthias

Abstract

Background & Aims: Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival remain an unmet need. Methods: Patients with HCC put on PD-(L)1-based immunotherapy were included in a training set (n = 190; 6 European centers) and a validation set (n = 102; 8 European centers). We investigated the prognostic value of baseline variables on overall survival using a Cox model in the training set and developed the easily applicable CRAFITY (CRP and AFP in ImmunoTherapY) score. The score was validated in the independent, external cohort, and evaluated in a cohort of patients treated with sor- afenib (n = 204). Results: Baseline serum alpha-fetoprotein >= 100 ng/ml (hazard ratio [HR] 1.7; p = 0.007) and C-reactive protein >= 1 mg/dl (HR, 1.7; p = 0.007) were identified as independent prognostic factors in multivariable analysis and were used to develop the CRAFITY score. Patients who fulfilled no criterion (0 points; CRAFITY-low) had the longest median overall survival (27.6 (95% CI 19.5-35.8) months), followed by those fulfilling 1 criterion (1 point; CRAFITY-intermediate; 11.3 (95% CI 8.0-14.6) months), and patients meeting both criteria (2 points; CRAFITY-high; 6.4 (95% CI 4.8-8.1) months; p <0.001). Additionally, best radiological response (complete response/partial response/stable disease/ progressive disease) was significantly better in patients with lower CRAFITY score (CRAFITY-low: 9%/20%/52%/20% vs. CRAFITY-intermediate: 3%/25%/36%/36% vs. CRAFITY-high: 2%/ 15%/22%/61%; p = 0.003). These results were confirmed in the independent validation set and in different subgroups, including Child-Pugh A and B, performance status 0 and >= 1 and first-line and later lines. In the sorafenib cohort, CRAFITY was associated with survival, but not radiological response. Conclusions: The CRAFITY score is associated with survival

Published
2022

13. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.

Author

Al-Batran, Salah-Eddin, primary, Lorenzen, Sylvie, additional, Thuss-Patience, Peter C., additional, Homann, Nils, additional, Schenk, Michael, additional, Lindig, Udo, additional, Heuer, Vera, additional, Kretzschmar, Albrecht, additional, Goekkurt, Eray, additional, Haag, Georg Martin, additional, Riera Knorrenschild, Jorge, additional, Bolling, Claus, additional, Hofheinz, Ralf-Dieter, additional, Angermeier, Stefan, additional, Ettrich, Thomas Jens, additional, Siebenhuener, Alexander, additional, Kopp, Christina, additional, Pauligk, Claudia, additional, Goetze, Thorsten Oliver, additional, and Gaiser, Timo, additional

Published
2022
Full Text
View/download PDF

14. FRI-273 - Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab

Author

Scheiner, Bernhard, Sartoris, Riccardo, D’Alessio, Antonio, Fulgenzi, Claudia, Pomej, Katharina, Balcar, Lorenz, Bouattour, Mohamed, Sidali, Sabrina, Himmelsbach, Vera, Finkelmeier, Fabian, Schulze, Kornelius, von Felden, Johann, Hucke, Florian, Shmanko, Kateryna, Siebenhüner, Alexander, Mertens, Joachim C., De Dosso, Sara, Ebert, Matthias, Teufel, Andreas, Waldschmidt, Dirk-Thomas, Radu, Iuliana Pompilia, Krall, Anja, Trauner, Michael, Dufour, Jean-François, Wege, Henning, Weinmann, Arndt, Trojan, Jörg, Stauber, Rudolf E., Peck-Radosavljevic, Markus, Hsu, Wei-Fan, Vogel, Arndt, Ronot, Maxime, Pinato, David J., and Pinter, Matthias

Published
2023
Full Text
View/download PDF

16. Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.

Author

Homann, Nils, primary, Lorenzen, Sylvie, additional, Schenk, Michael, additional, Thuss-Patience, Peter C., additional, Goekkurt, Eray, additional, Hofheinz, Ralf Dieter, additional, Kretzschmar, Albrecht, additional, Bolling, Claus, additional, Angermeier, Stefan, additional, Wicki, Andreas, additional, Siebenhuener, Alexander Rheinhard, additional, Lindig, Udo, additional, Pink, Daniel, additional, Ettrich, Thomas Jens, additional, Schmalenberg, Harald, additional, Waberer, Lisa, additional, Talbot, Jonathan, additional, Pauligk, Claudia, additional, Goetze, Thorsten Oliver, additional, and Al-Batran, Salah-Eddin, additional

Published
2020
Full Text
View/download PDF

18. Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.

Author

Al-Batran, Salah-Eddin, primary, Lorenzen, Sylvie, additional, Schenk, Michael, additional, Thuss-Patience, Peter C., additional, Goekkurt, Eray, additional, Hofheinz, Ralf, additional, Kretzschmar, Albrecht, additional, Bolling, Claus, additional, Angermeier, Stefan, additional, Wicki, Andreas, additional, Siebenhuener, Alexander Rheinhard, additional, Eigendorff, Ekkehard, additional, Pink, Christin, additional, Ettrich, Thomas Jens, additional, Schmalenberg, Harald, additional, Waberer, Lisa, additional, Talbot, Jonathan, additional, Pauligk, Claudia, additional, Goetze, Thorsten Oliver, additional, and Homann, Nils, additional

Published
2020
Full Text
View/download PDF

20. Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Author

Al-Batran, Salah-Eddin, primary, Pauligk, Claudia, additional, Hofheinz, Ralf, additional, Lorenzen, Sylvie, additional, Wicki, Andreas, additional, Siebenhuener, Alexander Rheinhard, additional, Schenk, Michael, additional, Welslau, Manfred, additional, Heuer, Vera, additional, Goekkurt, Eray, additional, Schmalenberg, Harald, additional, Thuss-Patience, Peter C., additional, Waberer, Lisa, additional, Talbot, Jonathan, additional, Goetze, Thorsten Oliver, additional, and Homann, Nils, additional

Published
2019
Full Text
View/download PDF

22. The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer.

Author

Posch, Florian, primary, Silina, Karina, additional, Petrausch, Ulf, additional, Leibl, Sebastian, additional, Muendlein, Axel, additional, Moch, Holger, additional, Siebenhuener, Alexander Rheinhard, additional, Pestalozzi, Bernhard C., additional, Riedl, Jakob M., additional, Stotz, Michael, additional, Szkandera, Joanna, additional, Stoger, Herbert, additional, Pichler, Martin, additional, Stupp, Roger, additional, Schraml, Peter, additional, Gerger, Armin, additional, and Winder, Thomas, additional

Published
2017
Full Text
View/download PDF

23. The fibrinogen/CRP ratio as a novel prognostic parameter for pancreatic cancer patients.

Author

Winder, Thomas, primary, Stotz, Michael, additional, Siebenhuener, Alexander Rheinhard, additional, Schlick, Konstantin, additional, Magnes, Teresa, additional, Samaras, Panagiotis, additional, Szkandera, Joanna, additional, Clavien, Pierre-Alain, additional, Neureiter, Daniel, additional, Greil, Richard, additional, Pestalozzi, Bernhard C., additional, Gerger, Armin, additional, Egle, Alexander, additional, and Pichler, Martin, additional

Published
2016
Full Text
View/download PDF

24. Sa1864 - Vegetarian and Gluten-Free Diet in Patients with IBD - Associated with a Different Microbiota Compared to Omnivore IBD Patients

Author

Schreiner, Philipp, Yilmaz, Bahtiyar, Franc, Yannick, Rossel, Jean-Benoit, Misselwitz, Benjamin, Scharl, Michael M., Zeitz, Jonas, Frei, Pascal, Greuter, Thomas, Vavricka, Stephan R., Pittet, Valerie, Siebenhüner, Alexander, Juillerat, Pascal, von Känel, Roland, Macpherson, Andrew, Rogler, Gerhard, and Biedermann, Luc

Published
2018
Full Text
View/download PDF

26. A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The...

Author

Al-Batran, Salah-Eddin, Lorenzen, Sylvie, Thuss-Patience, Peter C., Homann, Nils, Schenk, Michael, Lindig, Udo, Heuer, Vera, Kretzschmar, Albrecht, Goekkurt, Eray, Haag, Georg Martin, Riera-Knorrenschild, Jorge, Bolling, Claus, Hofheinz, Ralf-Dieter, Angermeier, Stefan, Ettrich, Thomas Jens, Siebenhuener, Alexander Reinhard, Kopp, Christina, Pauligk, Claudia, and Goetze, Thorsten Oliver

Published
2023
Full Text
View/download PDF

27. Multimodality Treatment Approach for Locally Advanced Pancreatic Cancer

Author

Clavien Pierre-Alain, Seifert Burckhardt, Mamot Christoph, Bodis Stephan, Datta Niloy, Siebenhuener Alexander, Pestalozzi Bernhard, De Oliveira Michelle, Samaras Panagiotis, Riesterer Oliver, and Winder Thomas

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Pancreatic cancer, Medicine, Combined Modality Therapy, Hematology, business, medicine.disease, Locally advanced pancreatic cancer
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results